Drugmaker Teva is considering making a bid for Mylan, but has not yet made a decision on an offer, Dow Jones reported.» Read More
Discussing the growth in the biotech industry, and current trading action, with Nasdaq OMX CEO Robert Greifeld.
After an abrupt departure, Former Teva CEO Jeremy Levin is now leading a start-up focused on rare neurological disorders.
Is it the golden age for cancer research Stephen Isaacs, Aduro Biotech CEO, discusses some of the advances in medicine of late.
Australia is making it harder for parents to file personal objections against vaccination.
Johnson & Johnson reports quarterly earnings that beat expectations despite a 7.2 percent drag on the strong dollar.
Drugmaker Mylan said a settlement would allow it to launch a generic version of the drug as early as December 2017.
It can cost $75,000 to $250,000, and the names keep getting stranger as companies balance regulator concerns with the desire to market the product.
CNBC "Fast Money" traders discussed how to trade big names in the surging but uncertain biotechnology sector.
The "Halftime Report" traders give their trades for the second half.
Barbara Ryan, Clermont Partners, discusses pharmaceutical consolidation including acquisitions and how to be a top player in the pharma sector.
Perrigo shares shot higher after news that Mylan proposed to buy Perrigo for $205 per share.
Eric Schmidt, senior research analyst at Cowen & Co, explains why despite the outperformance in the biotech sector, there's more room to run.
An estimated 3 million Americans have autism. But what exactly what is it, and where are we on treatments?
An intestinal illness called Shigellosis and carried by international travelers is spreading across the U.S., according to the Centers for Disease Control and Prevention.
CNBC's Meg Tirrell takes a deeper look at Autism, the people it affects and where treatment stands.
Merrimack CEO Bob Mulroy joins CNBC's Meg Tirrell to discuss the Merrimack development pipeline for nanotherapeutic chemotherapy.
Sam Isaly, OrbiMed Advisors managing partner, says valuations are more than they used to be but adds, they're not crazy, they're sensible. He shares his view of the biotech sector.
As gene therapy emerges in the biotech industry, one analyst explains why it could be the next billion dollar industry.
Andrew Morey, portfolio manager at ASTON LMCG Small Cap Growth Fund, attributes the rally in U.S. biotech shares to "fundamental merits" like clinical advances.
A national pharmacists' group has adopted a policy discouraging its members from providing death-penalty drugs.
Get the best of CNBC in your inbox